On the fly News and insights, exclusive to thefly.com

2020-06-05 10:06:20 NVAX Novavax $49.70 / +5.02 (+11.24%) , NAV Navistar $29.22 / +1.3 (+4.66%) … 10:06 06/05/20 06/05 10:06 06/05/20 10:06	Fly Intel: Top five analyst upgrades Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Novavax (NVAX) upgraded to Neutral from Underweight at JPMorgan with analyst Eric Joseph saying the stock's 995% rally year-to-date reflects the potential promise for the company's COVID-19 vaccine program, NVX-CoV2373, having recently initiated phase 1 testing. 2. Navistar (NAV) was upgraded to Outperform from Neutral at Baird and to Buy from Hold at Loop Capital. 3. Sysco (SYY) upgraded to Overweight from Equal Weight at Wells Fargo with analyst Edward Kelly saying Kelly's confidence in the company's ability to navigate the COVID-19 disruption and emerge even stronger is growing. 4. Hexcel (HXL) upgraded to Outperform from Market Perform at BMO Capital with analyst John McNulty saying while the company's near-term earnings will be "abysmal" with significant production cuts in aerospace compounded by inventory destocking that can't be offset quickly enough with cost cutting, there are improving signs for the intermediate to long term with the 737 MAX ramp-up having started. 5. Westpac (WBK) upgraded to Buy from Neutral at UBS with analyst Jonathan Mott saying he Australian banks have de-rated but the outlooks "may not be as bleak." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. NVAX Novavax $49.70 / +5.02 (+11.24%) NAV Navistar $29.22 / +1.3 (+4.66%) SYY Sysco $63.09 / +4.51 (+7.70%) HXL Hexcel $48.77 / +4.055 (+9.07%) WBK Use WEBNF $13.51 / +0.7 (+5.46%)	08 Jun 23 Jun 25 Jun

2020-06-05 10:06:20

NVAX

Novavax

$49.70 / +5.02 (+11.24%)

, NAV

Navistar

$29.22 / +1.3 (+4.66%)

… 10:06

06/05/20

06/05

10:06

06/05/20

10:06

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Novavax (NVAX) upgraded to Neutral from Underweight at JPMorgan with analyst Eric Joseph saying the stock's 995% rally year-to-date reflects the potential promise for the company's COVID-19 vaccine program, NVX-CoV2373, having recently initiated phase 1 testing. 2. Navistar (NAV) was upgraded to Outperform from Neutral at Baird and to Buy from Hold at Loop Capital. 3. Sysco (SYY) upgraded to Overweight from Equal Weight at Wells Fargo with analyst Edward Kelly saying Kelly's confidence in the company's ability to navigate the COVID-19 disruption and emerge even stronger is growing. 4. Hexcel (HXL) upgraded to Outperform from Market Perform at BMO Capital with analyst John McNulty saying while the company's near-term earnings will be "abysmal" with significant production cuts in aerospace compounded by inventory destocking that can't be offset quickly enough with cost cutting, there are improving signs for the intermediate to long term with the 737 MAX ramp-up having started. 5. Westpac (WBK) upgraded to Buy from Neutral at UBS with analyst Jonathan Mott saying he Australian banks have de-rated but the outlooks "may not be as bleak." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

NVAX

Novavax